(VIANEWS) – Wintrust Financial Corporation (WTFC), Acadia Healthcare Company (ACHC), Sysco Corporation (SYY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Wintrust Financial Corporation (WTFC)
13.3% sales growth and 11.83% return on equity
Wintrust Financial Corporation operates as a financial holding company. It operates in three segments: Community Banking, Specialty Finance, and Wealth Management. The Community Banking segment offers non-interest bearing deposits, non-brokered interest-bearing transaction accounts, and savings and domestic time deposits; home equity, consumer, and real estate loans; safe deposit facilities; and automatic teller machine (ATM), online and mobile banking, and other services. It also engages in the retail origination and purchase of residential mortgages for sale into the secondary market; and provision of lending, deposits, and cash management services to condominium, homeowner, and community associations, as well as asset-based lending for middle-market companies. In addition, this segment offers loan and deposit services to mortgage brokerage companies; lending to restaurant franchisees; direct leasing; small business administration loans; commercial mortgages and construction loans; and financial solutions. It provides personal and commercial banking services primarily to individuals, small to mid-sized businesses, local governmental units, and institutional clients. The Specialty Finance segment offers commercial and life insurance premiums financing for businesses and individuals; accounts receivable financing, value-added, and out-sourced administrative services; and other specialty finance services, as well as data processing of payrolls, billing, and cash management services to temporary staffing industry. The Wealth Management segment provides trust and investment, asset management, tax-deferred exchange, securities brokerage, and retirement plan services. The company operates 181 banking facilities and 229 ATMs in the Chicago metropolitan area, southern Wisconsin, northwest Indiana, and Florida. Wintrust Financial Corporation was founded in 1991 and is headquartered in Rosemont, Illinois.
Earnings Per Share
As for profitability, Wintrust Financial Corporation has a trailing twelve months EPS of $8.75.
PE Ratio
Wintrust Financial Corporation has a trailing twelve months price to earnings ratio of 7.53. Meaning, the purchaser of the share is investing $7.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.83%.
Moving Average
Wintrust Financial Corporation’s value is below its 50-day moving average of $68.47 and way below its 200-day moving average of $82.91.
2. Acadia Healthcare Company (ACHC)
7.9% sales growth and 10.21% return on equity
Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the United States and Puerto Rico. The company operates acute inpatient psychiatric facilities, which cares to stabilize patients that are either threat to themselves or 24-hour observation, daily intervention, and monitoring by psychiatrists; and specialty treatment facilities, including residential recovery and eating disorder facilities, and comprehensive treatment centers that provide continuum care for adults with addictive disorders and co-occurring mental disorders. It also provides residential treatment centers, which treat patients with behavioral disorders in a non-hospital setting, including outdoor programs; and offer therapeutic placement for children and adolescents with emotional disorders. As of February 28, 2022, it operated a network of 228 behavioral healthcare facilities with approximately 10,500 beds. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.
Earnings Per Share
As for profitability, Acadia Healthcare Company has a trailing twelve months EPS of $3.06.
PE Ratio
Acadia Healthcare Company has a trailing twelve months price to earnings ratio of 22.56. Meaning, the purchaser of the share is investing $22.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.21%.
3. Sysco Corporation (SYY)
6.7% sales growth and 104.39% return on equity
Sysco Corporation, through its subsidiaries, engages in the marketing and distribution of various food and related products primarily to the foodservice or food-away-from-home industry in the United States, Canada, the United Kingdom, France, and internationally. It operates through U.S. Foodservice Operations, International Foodservice Operations, SYGMA, and Other segments. The company distributes frozen food, such as meat, seafood, fully prepared entrées, fruits, vegetables, and desserts; canned and dry food products; fresh meat and seafood products; dairy products; beverages; imported specialties; and fresh produce products. It also supplies various non-food items, including paper products comprising disposable napkins, plates, and cups; tableware consisting of China and silverware; cookware, which include pots, pans, and utensils; restaurant and kitchen equipment and supplies; and cleaning supplies. The company serves restaurants, hospitals and nursing homes, schools and colleges, hotels and motels, industrial caterers, and other foodservice venues. As of July 2, 2022, it operated 333 distribution facilities. Sysco Corporation was incorporated in 1969 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Sysco Corporation has a trailing twelve months EPS of $3.02.
PE Ratio
Sysco Corporation has a trailing twelve months price to earnings ratio of 23.88. Meaning, the purchaser of the share is investing $23.88 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 104.39%.
Moving Average
Sysco Corporation’s value is under its 50-day moving average of $74.65 and under its 200-day moving average of $78.14.
4. United Therapeutics Corporation (UTHR)
6% sales growth and 15.66% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $14.49.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 14.31. Meaning, the purchaser of the share is investing $14.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.66%.
Moving Average
United Therapeutics Corporation’s value is under its 50-day moving average of $221.14 and way under its 200-day moving average of $238.34.
Yearly Top and Bottom Value
United Therapeutics Corporation’s stock is valued at $207.32 at 20:22 EST, way under its 52-week high of $283.09 and higher than its 52-week low of $201.65.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.7%, now sitting on 1.98B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 87.1% and a drop 2.9% for the next.
